PAD2 serves as a pro-fibrotic mediator in fibroblasts of patients with RA-ILD, and its suppression reduces fibroblast–myofibroblast transition (FMT) and extracellular matrix formation [95]. Here, PADI2 is linked to rheumatoid arthritis.